Letter from the Editor

Dear Readers,

Thank you very much for your interest in the ESC 2021 Medicom Conference Report. This ESC Congress saw a rich mix of guideline updates, hotline sessions and innovative science. You will find summaries of new Guidelines introduced on heart failure, valvular disease, cardiac resynchronization, and prevention.

Key hotlines were presented including the awaited data on empagliflozin and its effects in patients with heart failure with preserved ejection fraction, a high-risk population with few proven therapies. Additional hotlines covered blood pressure control, management of patients after cardiac arrest, app-based interventions, and more data on the effects of polypills in primary prevention. Additional presentations also covered key topics such as COVID-19, vascular disease, and valvular heart disease.

We hope that you will find the enclosed summaries of great interest. Through our independent review process, we strive to provide informative and balanced summaries in a succinct and approachable format with the hopes that you can learn of some of the top scientific presentations from this important meeting. Unfortunately, with space limitations, we are unable to capture all presentations but we have provided a selection that we hope provides a sense of key learnings. Thank you again and please accept our best wishes for a safe and healthy season.

 

Sincerely,

Marc Bonaca MD MPH



 

Biography

Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi



Posted on 26 October, 2021